Targeting non-coding RNAs to overcome cancer therapy resistance

被引：265

作者：

Chen, BaoQing ^{[1
]}

Dragomir, Mihnea P. ^{[2
,3
,4
,5
,6
,7
]}

Yang, Chen ^{[1
]}

Li, Qiaoqiao ^{[1
]}

Horst, David ^{[2
,3
,4
,5
,7
]}

Calin, George A. ^{[8
,9
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Radiat Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China

[2] Charite Univ Med Berlin, Inst Pathol, D-10117 Berlin, Germany

[3] Free Univ Berlin, D-10117 Berlin, Germany

[4] Humboldt Univ, D-10117 Berlin, Germany

[5] Berlin Inst Hlth, D-10117 Berlin, Germany

[6] Berlin Inst Hlth, Anna Louisa Karsch Str 2, D-10178 Berlin, Germany

[7] German Canc Res Ctr, German Canc Consortium DKTK, Partner Site Berlin, D-69210 Heidelberg, Germany

[8] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA

[9] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2022年 / 7卷 / 01期

基金：

中国国家自然科学基金;

关键词：

BREAST-CANCER; COLORECTAL-CANCER; DRUG-RESISTANCE; CHROMOSOMAL INSTABILITY; CLINICAL-IMPLICATIONS; MOLECULAR-MECHANISMS; BLADDER-CANCER; CELL CARCINOMA; MICRORNA; EXPRESSION;

D O I：

10.1038/s41392-022-00975-3

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Despite recent discoveries in cancer therapy, resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy continue to be a major setback. Recent studies have shown that ncRNAs also play a major role in resistance to different cancer therapies by rewiring essential signaling pathways. In this review, we present the intricate mechanisms through which dysregulated ncRNAs control resistance to the four major types of cancer therapies. We will focus on the current clinical implications of ncRNAs as biomarkers to predict treatment response (intrinsic resistance) and to detect resistance to therapy after the start of treatment (acquired resistance). Furthermore, we will present the potential of targeting ncRNA to overcome cancer treatment resistance, and we will discuss the challenges of ncRNA-targeted therapy-especially the development of delivery systems.

引用

页数：20

共 176 条

[1] Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia [J].